It would seem to me that in the current climate where vaccines are being hailed one minute and dismissed the next that any Covid trial which is under 50% complete would be more more difficult to hail as a breakthrough.
Therefore going to at least 60% tested before the trial could be halted for efficacy would seem better for all parties MSB, FDA, and most importantly the sick.
Ann: DSMB Analysis Recommends to Continue P3 COVID-19 ARDS Trial, page-113
Add MSB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
95.0¢ |
Change
-0.005(0.52%) |
Mkt cap ! $1.084B | |||
| Open | High | Low | Value | Volume |
| 96.0¢ | 98.5¢ | 91.5¢ | $4.743M | 4.999M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 3 | 123302 | 95.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 95.5¢ | 314 | 1 |
View Market Depth
| Last trade - 16.10pm 29/08/2024 (20 minute delay) ? |
| MSB (ASX) Chart |